A long term bone and renal safety of TAF treatment on renal transplant recipients
Our results suggest that TAF provides favorable efficacy, renal safety, and tolerability in KTRs. ETV also provided effective and sustainable viral suppression. TAF may offer additional advantages such as no concern of viral resistance and dose adjustment by eGFR levels for long-term management of HBsAg-positive KTRs.
Authors
- David Tak Wai Lui (ORCID: https://orcid.org/0000-0002-9813-1126)
- Cheng‐Kun Wu
- Kuo‐Chin Chang
- Wen‐Chin Lee (ORCID: https://orcid.org/0000-0001-6172-1483)
- Tsung‐Hui Hu (ORCID: https://orcid.org/0000-0002-9172-1967)
- Tak Mao Chan (ORCID: https://orcid.org/0000-0002-3495-4051)
- Desmond Y. H. Yap (ORCID: https://orcid.org/0000-0001-8179-8293)
- Colin Tang
- Maggie K.M.
Institutions
- Queen Mary Hospital (CN)
- Kaohsiung Chang Gung Memorial Hospital (TW)
- University of Hong Kong (HK)
Publication Details
- Journal
- Biomedical Journal
- Published
- 2025-02-15
- DOI
- https://doi.org/10.1016/j.bj.2025.100833
- Citations
- 5
- Primary Topic
- Bone and Joint Diseases
- Type
- article
- Field-Weighted Citation Impact
- 8.61